The implementation of the ICH S7B and E14 guidelines has been successful in preventing the introduction of potentially torsadogenic drugs to the market, but it has also unduly constrained drug development by focusing on hERG block and QT prolongation as essential determinants of proarrhythmia risk.
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress
Journal of Pharmacological and Toxicological Methods, 2016